Gus Gazzard, MA(Cantab), MD, MBBChir, FRCOphth
Show Description +
Gus Gazzard, FRCOphth, MA, MBBChir, MD, analyzes the 6-year rate of visual field progression in the laser in glaucoma and ocular hypertension (LiGHT) trial comparing selective laser trabeculoplasty (SLT) and medication as first-line glaucoma treatment. He reviews information presented during glaucoma subspecialty day at the American Academy of Ophthalmology annual meeting.
Posted: 10/25/2024
Gus Gazzard, MA(Cantab), MD, MBBChir, FRCOphth
Gus Gazzard, FRCOphth, MA, MBBChir, MD, analyzes the 6-year rate of visual field progression in the laser in glaucoma and ocular hypertension (LiGHT) trial comparing selective laser trabeculoplasty (SLT) and medication as first-line glaucoma treatment. He reviews information presented during glaucoma subspecialty day at the American Academy of Ophthalmology annual meeting.
Posted: 10/25/2024
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2024.
Please log in to leave a comment.